parallel randomized trial

S003059

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)S003059

Design

Randomized: 60
Start year: 2015
Treatment: 8 weeks, follow-up 8 weeks
Countries: China (1 sites)
Sponsor: (non industry)
Eligibility: age 18 to 40; BMI 25 to 35; HbA1c 6.5 to 9 percent; new onset drug naive T2D

Conduct and analysis

Blinding: open label
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Liraglutide 1.2 mg subcutaneous once daily Liraglutide	lifestyle: standard
A2	Metformin Metformin	lifestyle: standard

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Liraglutide 1.2 mg subcutaneous once daily A1	Metformin A2
bmi	mean (kg/m2)	28.63
bmi	sd (kg/m2)	3.86
hba1c	mean (percent)	8.36	8.35
hba1c	sd (percent)	0.55	0.55
waist	mean (cm)	92	88
waist	sd (cm)	12	8

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
8	A1	final	6.85 percent	0.71			not stated; other; R0025073:Results
8	A2	final	6.53 percent	0.65			not stated; other; R0025073:Results